Testing VENT-03 for active skin lupus with or without systemic lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have active skin lupus (such as discoid or subacute cutaneous lupus) with a certain severity on your skin.
- If you also have systemic lupus (SLE), your lupus must be confirmed by a positive ANA blood test and you must be on stable lupus medications.
- You cannot have other serious health conditions such as active infections, certain cancers, severe liver problems, or other autoimmune diseases that could interfere with the study.
- You cannot have taken high-dose steroids for more than 2 weeks in the last 6 months for a non-lupus condition.
- You must not have had a lupus flare severe enough for hospitalization in the past 3 months or active kidney or brain lupus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.